AzTrials
AzTrials

Surgical Site InfectionEarly Phase 1NCT03853096

P.Acnes Colony Count Following Subdermal Cefazolin

A Early Phase 1 study testing Cefazolin in people with Surgical Site Infection and Microbial Colonization, run by University of British Columbia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The specific outcome is to determine whether the colony count of Propionibacterium acnes, one of the commonest causes of shoulder infection and not eradicated by conventional forms of surgical preparatory solutions and antibiotics, in a shoulder surgical wound will be altered by the use of subdermal cefazolin. Read more about this study

Who is it for?
Ages 18 to 90 yearsHealthy volunteers can take part
What is being tested?
Cefazolin
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
No sites listed yet
Study dates
1 Apr 2019to 1 Apr 2020
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • age greater than or equal to 18
  • patients requiring deltopectoral approach and opening of joint capsule for primary shoulder surgery

Who cannot join

  • allergy to cefazolin or cephalosporins
  • tattoos over operative site
  • previous surgical site infections in either shoulder
  • revision surgical procedure
  • immunocompromised patients

Trial locations and contacts

No sites are listed yet.

William Regan contact

1-866-737-7460

bill.regan@ubc.ca

Ryan Lohre contact

1-604-317-3275

About this study

Official title: Do Intra-incisional Subdermal Antibiotics Alter the Colony Count of P. Acnes

The specific outcome is to determine whether the colony count of Propionibacterium acnes, one of the commonest causes of shoulder infection and not eradicated by conventional forms of surgical preparatory solutions and antibiotics, in a shoulder surgical wound will be altered by the use of subdermal cefazolin.

Read the detailed description

Purpose The purpose of the study is to review if the subdermal injection of antibiotics intraoperatively reduces the bacterial load in the subcutaneous tissue during the course of an open shoulder operation.

Null Hypothesis There will be no change in the colony count of P.acnes following administration of subdermal antibiotics.

Justification. P. Acnes is the most common cause of shoulder infection. The incidence of post-operative shoulder joint infection varies from 4-18%. The P.acnes organism is a Gram positive, largely anaerobic but aerotolerant commensal of the deep skin follicles and standard skin preparation may inadequately penetrate the pilosebaceous follicles. It has also been shown in a study by Levy et al that 41.8% of patients had a positive biopsy or aspirate result for P.acnes prior to implantation of components. This study will determine whether intraoperative subdermal antibiotic administration reduces the bacterial load and in turn reduce the incidence of shoulder joint infection. Cefazolin has been chosen because cephalosporins and penicillins have the lowest minimum inhibitory concentration (MIC) against P.acnes. There is a lower incidence of allergy to cephalosporins than penicillins. This study has the potential to change clinical practice world wide.

Objectives The specific outcome is to compare the bacterial cell count on either side of a surgical wound and determine if subcutaneous antibiotics on a single side reduces subcutaneous cell counts over various time courses throughout the operation.

Research Method. Targeted recruitment is 20 patients in this pilot study. This figure has been arrived at after determining the power of the study, significance levels and the anticipated drop in P.acnes count colonisation after the use of local antibiotics. It is also a number that can be achieved rapidly, enabling us to assess whether there is an observed difference between the groups and thereby gauge the feasibility of a larger trial.

The patients will receive the standard of care pre-operative antibiotics 30 minutes prior to incision and surgical intervention. The skin will also be prepped using a chlorhexidine alcohol based solution as is standard at the investigator's institution. The investigators will divide the normal surgical incision into three even sections on either side of the incision, thus forming six segments. One side of the wound will be injected with three aliquots of 3 mLs using a concentration 100mg/mL of cefazolin. This equates to 900mg of subcutaneous cefazolin antibiotic. There are no specific efficacy criteria for agents in this setting that have been standardised and approved by an official oversight agency. We have selected this quantity based upon safe and wide-spread use of this concentration in a systemic manner as well as being mindful of the readily available concentrations. There is no known study describing any harm on introduction of antibiotics into the soft tissue, e.g. vancomycin used topically in prosthetic joints as a prophylaxis against infection, and the widespread use of intra-muscular (IM) penicillin products. Subcutaneous cefazolin has been demonstrated as safe in a porcine model while delivering higher cutaneous concentrations than with comparative systemic administration. Subcutaneous ceftriaxone is approved for use in France and is of increasing use for geriatric populations as well as by infectious disease practitioners. There is published evidence of safe administration of cefazolin in tumescent anesthesia antibiotic delivery mixed with lidocaine, epinephrine, and sodium bicarbonate.

Standardized samples from all six sections will be sampled using a disposable 6mm Mitex biopsy punch before inoculation and this process will be repeated at the 60 minute mark. The samples will be sent to the microbiology lab where colony count will be obtained and long term cultures i.e. 3 weeks will be performed.

It is routine in surgery to inject subcutaneous substances and not infrequently biopsies are taken. The only potential side effect is allergy to cephalosporins, which would have been determined preoperatively and is part of the exclusion criteria. There will be no expected increased incidence of infection or bleeding.

Collection, Handling and Storage Specimens will be labeled with appropriate patient identifiers and clearly labeled as to the site of collection, and sent to the laboratory immediately for processing as soon as possible. Tissue biopsies will be sent either in anaerobic transport media or in a sterile container with a piece of sterile gauze moistened with non-bacteriostatic saline, or if piece is large enough, just a few drops of non-bacteriostatic in the container to prevent the tissue from desiccation.

Tissue Processing All specimen manipulations will be carried out in the Biological Safety Cabinet and processed as soon as possible. Tissues will be inoculated to media to maximize the recovery of Propionibacterium acnes which will include a 5% sheep's blood agar and chocolate agar plates and thioglycollate (THIO) broth incubated under 5% carbon dioxide (CO2) at 35 Celsius. Brucella and Columbia Naladixic acid (CNA) agars will be incubated in an anaerobic conditions at 35 Celsius.

With sterile forceps, the tissue will be transferred to a sterile Petri plate. Using a disposable sterile scalpel the tissue will be chopped into enough small pieces to inoculate all the media required. Several pieces of tissue will be added to THIO broth. The remaining media will be inoculated if order of least selective to the most selective: the blood agar plate, chocolate agar plate, Brucella and CNA agar.

Lastly "touch preps" for the gram smears will be performed by gently touching a fresh piece of tissue onto the microscope slides. This piece of tissue will be discarded as it now is potentially contaminated.

Tissue Investigation

All media will be incubated for 5 days and read daily. The broth will be held for 21 days and examined at 7, 14 and 21 days after the initial 5 day reads. There is no need to follow the patients up for 2 years as we are only looking to determine change in intra operative colony counts which can be determined within 21 days and may be linked to a reduction in infection.

All bacterial growth will be investigated per usual laboratory procedures for identification and antimicrobial susceptibility testing.

Results will be reported to the study investigators in a timely fashion

Statistical Analysis. Samples will be compared with either side of the wound over the respective time periods. Count averages will be obtained and analysised using a paired t-test.

Being tested
Cefazolin
Medical subject headings
Surgical Wound Infection, Communicable Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CefazolinDrug

    Cefazolin 100mg/mL, 3mL in three locations will be administered around a surgical incision on the anterior shoulder in a standard deltopectoral approach interval. This will be a one time administration. Administration and route will be subcutaneous.

Study groups in NCT03853096
Study groupRoleWhat they receive
Subcutaneous cefazolin armExperimentalA patient receiving a standard deltopectoral approach will have the planned incision site divided into thirds. This will produce 6 segments. Each segment will be biopsied using a commercially available dermatology punch and sent for colony count prior to local antibiotic infiltration. Cefazolin will be administered to one half of the incision only, into three segments. Following 60 minutes of operative time, the biopsies will be repeated and sent for colony count for comparison. Cefazolin administered will be 100mg/mL in 3 aliquots for 3 site administrations leading to a total subcutaneous injection of approximately 900mg. There will be a one time administration of the antibiotics in a subcutaneous route.
Receives: Drug: Cefazolin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in P.acnes colony count

    Colony count before and 60 minutes after subcutaneous cefazolin administration

    Measured: Baseline tissue sampling prior to subcutaneous antibiotic administration, and tissue sampling 60 minutes after

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Feb 2019
  2. Study start1 Apr 2019 (estimated)
  3. Primary completion1 Apr 2020 (estimated)
  4. Study completion1 Apr 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Model description
20 patient pilot study, single arm prospectively collected with no blinding or randomization. Consenting patients will receive at time of surgery an additional subcutaneous cefazolin injection at the surgical site as well as timed tissue biopsies for colony count of P.acnes
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03853096
Sponsor's protocol ID
H16-01432
Status last verified
Feb 2019
First submitted
20 Feb 2019
Last updated
25 Feb 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin. 2010 Feb;26(2):279-88. doi: 10.1185/03007990903432900.

    PubMed 19947907
  • Quendt J, Blank I, Seidel W. [Peritoneal and subcutaneous administration of cefazolin as perioperative antibiotic prophylaxis in colorectal operations. Prospective randomized comparative study of 200 patients]. Langenbecks Arch Chir. 1996;381(6):318-22. doi: 10.1007/BF00191311. German.

    PubMed 9082104
  • Achermann Y, Goldstein EJ, Coenye T, Shirtliff ME. Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen. Clin Microbiol Rev. 2014 Jul;27(3):419-40. doi: 10.1128/CMR.00092-13.

    PubMed 24982315
  • Klein JA, Langman LJ. Prevention of Surgical Site Infections and Biofilms: Pharmacokinetics of Subcutaneous Cefazolin and Metronidazole in a Tumescent Lidocaine Solution. Plast Reconstr Surg Glob Open. 2017 May 30;5(5):e1351. doi: 10.1097/GOX.0000000000001351. eCollection 2017 May.

    PubMed 28607871
  • Saper D, Capiro N, Ma R, Li X. Management of Propionibacterium acnes infection after shoulder surgery. Curr Rev Musculoskelet Med. 2015 Mar;8(1):67-74. doi: 10.1007/s12178-014-9256-5.

    PubMed 25596729
  • Noriega OD, Yarleque Leon SN. Antibiotics by Subcutaneous Route: A Safe and Efficient Alternative. J Am Med Dir Assoc. 2018 Jun;19(6):553-554. doi: 10.1016/j.jamda.2018.03.011. Epub 2018 Apr 27. No abstract available.

    PubMed 29709392
  • Dubrovsky G, Huynh N, Rouch JD, Koulakis JP, Nicolau DP, Sutherland CA, Putterman S, Dunn JCY. Subcutaneous cefazolin to reduce surgical site infections in a porcine model. J Surg Res. 2018 Apr;224:156-159. doi: 10.1016/j.jss.2017.11.056. Epub 2017 Dec 28.

    PubMed 29506833
  • Forestier E, Paccalin M, Roubaud-Baudron C, Fraisse T, Gavazzi G, Gaillat J. Subcutaneously administered antibiotics: a national survey of current practice from the French Infectious Diseases (SPILF) and Geriatric Medicine (SFGG) society networks. Clin Microbiol Infect. 2015 Apr;21(4):370.e1-3. doi: 10.1016/j.cmi.2014.11.017. Epub 2014 Nov 23.

    PubMed 25658521
  • Cockshott WP, Thompson GT, Howlett LJ, Seeley ET. Intramuscular or intralipomatous injections? N Engl J Med. 1982 Aug 5;307(6):356-8. doi: 10.1056/NEJM198208053070607. No abstract available.

    PubMed 7088101
  • Levy PY, Fenollar F, Stein A, Borrione F, Cohen E, Lebail B, Raoult D. Propionibacterium acnes postoperative shoulder arthritis: an emerging clinical entity. Clin Infect Dis. 2008 Jun 15;46(12):1884-6. doi: 10.1086/588477.

    PubMed 18462110

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Cefazolin in people with Surgical Site Infection and Microbial Colonization, run by University of British Columbia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact William Regan (1-866-737-7460, bill.regan@ubc.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in P.acnes colony count (time frame: Baseline tissue sampling prior to subcutaneous antibiotic administration, and tissue sampling 60 minutes after). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03853096, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in